Education
About Us
Working with TipRanks
Follow Us
Renascience Inc. (JP:4889)
:4889
Top Page
Renascience Inc.
(4889)
Rating:51Neutral
Price Target:―
Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥23.99B
Dividend YieldN/A
Average Volume (3M)2.55M
Price to Earnings (P/E)211.5
Beta (1Y)0.45
Revenue Growth-27.27%
EPS GrowthN/A
CountryJP
Employees4
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.20
Shares Outstanding12,711,700
10 Day Avg. Volume2,946,930
30 Day Avg. Volume2,546,670
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)7.02
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renascience Inc. Business Overview & Revenue Model
Company DescriptionRenascience Inc. (4889) is a cutting-edge biotechnology company specializing in the development and commercialization of innovative solutions for regenerative medicine. The company focuses on harnessing the power of stem cell technology and tissue engineering to address unmet medical needs in various therapeutic areas. Renascience Inc. is committed to advancing healthcare by providing transformative products and services that enhance the quality of life for patients worldwide.
How the Company Makes MoneyRenascience Inc. generates revenue primarily through the sale of its proprietary regenerative medicine products and technologies. The company's key revenue streams include direct sales to healthcare providers, licensing agreements with pharmaceutical companies, and strategic partnerships with research institutions. Additionally, Renascience Inc. may receive funding from government grants and private investors to support its research and development activities. The company leverages its advanced scientific capabilities and expertise to maintain a competitive edge in the biotechnology sector, driving sustainable growth and profitability.
Renascience Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 138.39M | 194.16M | 100.55M | 139.33M | 209.80M | 72.00M | Gross Profit |
| 133.15M | 165.64M | 100.30M | 80.97M | 179.82M | 52.00M | EBIT |
| -169.92M | -252.34M | -333.87M | -210.84M | -86.13M | -183.00M | EBITDA |
| -150.88M | -250.50M | -332.49M | -244.65M | -80.36M | -180.08M | Net Income Common Stockholders |
| 118.14M | -258.33M | -335.80M | -254.29M | -100.05M | -184.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.84B | 2.03B | 2.21B | 2.39B | 1.03B | 980.00M | Total Assets |
| 1.91B | 2.09B | 2.27B | 2.44B | 1.07B | 1.01B | Total Debt |
| 0.00 | 356.10M | 309.60M | 199.23M | 475.65M | 380.00M | Net Debt |
| -1.84B | -1.67B | -1.90B | -2.19B | -549.99M | -600.00M | Total Liabilities |
| 147.00M | 482.11M | 409.76M | 237.17M | 505.10M | -1.00K | Stockholders Equity |
| 1.76B | 1.61B | 1.87B | 2.20B | 561.53M | 621.00M |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | -232.10M | -286.87M | -231.66M | -90.27M | -178.31M | Operating Cash Flow |
| 0.00 | -230.52M | -284.64M | -230.49M | -89.25M | -178.31M | Investing Cash Flow |
| 0.00 | -1.57M | 232.00K | -296.00K | -1.72M | -380.70M | Financing Cash Flow |
| 0.00 | 46.50M | 110.37M | 1.59B | 135.65M | 380.00M |
Renascience Inc. Technical Analysis
Positive
1864.00
Price Trends
1240.26
Positive
1191.25
Positive
754.87
Positive
Market Momentum
162.67
Negative
69.76
Neutral
79.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Positive. The current price of 1864 is above the 20-day moving average (MA) of 1542.45, above the 50-day MA of 1240.26, and above the 200-day MA of 754.87, indicating a bullish trend. The MACD of 162.67 indicates Negative momentum. The RSI at 69.76 is Neutral, neither overbought nor oversold. The STOCH value of 79.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4889.
Renascience Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥2.15T | 12.20 | 12.99% | 2.67% | 0.73% | 7.75% | |
79 Outperform | ¥12.06T | 29.42 | 22.80% | 1.25% | 17.96% | 25.65% | |
78 Outperform | $2.51T | 49.23 | 3.22% | 5.06% | 19.25% | 294.48% | |
71 Outperform | $1.13T | 24.43 | 5.34% | 4.20% | 6.42% | 11.00% | |
67 Neutral | ¥6.61T | 22.75 | 17.60% | 1.58% | 17.77% | 48.97% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
51 Neutral | ¥23.99B | 211.48 | ― | -27.27% | ― |
* Healthcare Sector Average
Performance Comparison
JP:4889
Renascience Inc.
1,887.00
1,524.00
419.83%
JP:4503
Astellas Pharma
1,396.00
-108.58
-7.22%
JP:4519
Chugai Pharmaceutical Co
7,619.00
2,841.94
59.49%
JP:4507
Shionogi & Co
2,443.50
401.26
19.65%
JP:4523
Eisai Co
3,948.00
-2,701.06
-40.62%
JP:4568
Daiichi Sankyo Company
3,485.00
-2,221.33
-38.93%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.